Chinese-led study revolutionizes urothelial cancer treatment
Phase III study of disitamab vedotin plus toripalimab shows significant improvement in PFS and OS for HER2-expressing urothelial carcinoma, potentially establishing new standard of care.
Telitacicept shows promise in Sjögren's Syndrome trial
Telitacicept demonstrated significant improvements in Sjögren's Syndrome in China Phase III trial, meeting primary and secondary endpoints with favorable safety profile.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.